SG11202007494TA - Anti-folate receptor 1 antibodies and uses thereof - Google Patents
Anti-folate receptor 1 antibodies and uses thereofInfo
- Publication number
- SG11202007494TA SG11202007494TA SG11202007494TA SG11202007494TA SG11202007494TA SG 11202007494T A SG11202007494T A SG 11202007494TA SG 11202007494T A SG11202007494T A SG 11202007494TA SG 11202007494T A SG11202007494T A SG 11202007494TA SG 11202007494T A SG11202007494T A SG 11202007494TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- folate receptor
- folate
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642213P | 2018-03-13 | 2018-03-13 | |
| PCT/US2019/021084 WO2019177854A1 (en) | 2018-03-13 | 2019-03-07 | Anti-folate receptor 1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007494TA true SG11202007494TA (en) | 2020-09-29 |
Family
ID=67906883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007494TA SG11202007494TA (en) | 2018-03-13 | 2019-03-07 | Anti-folate receptor 1 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11873335B2 (en) |
| EP (1) | EP3765521A4 (en) |
| JP (2) | JP7433236B2 (en) |
| KR (1) | KR20200132900A (en) |
| CN (2) | CN111954681B (en) |
| AU (1) | AU2019236091A1 (en) |
| BR (1) | BR112020016469A2 (en) |
| CA (1) | CA3091683A1 (en) |
| EA (1) | EA202092125A1 (en) |
| IL (1) | IL276949A (en) |
| MX (1) | MX2020009522A (en) |
| SG (1) | SG11202007494TA (en) |
| WO (1) | WO2019177854A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102275930B1 (en) | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Antibody specifically binding to FOLR1 and Use thereof |
| TW202233684A (en) * | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | Heavy chain antibodies binding to folate receptor alpha |
| CN115491358A (en) * | 2021-06-17 | 2022-12-20 | 复星凯特生物科技有限公司 | Preparation and application of targeting B7-H3 and FOLR1 double targeting CAR T |
| CN116462768B (en) * | 2023-06-13 | 2023-09-22 | 浙江时迈药业有限公司 | Bispecific antibodies against FOLR1 and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| AU2006241099B2 (en) | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| WO2008145136A1 (en) | 2007-05-30 | 2008-12-04 | Aarhus Universitet | Stat3 inactivation by inhibition of the folate receptor pathway |
| FR2929946B1 (en) * | 2008-04-11 | 2010-05-28 | Pf Medicament | NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| IL290617B2 (en) | 2010-02-24 | 2023-11-01 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| JP2014505012A (en) | 2010-10-20 | 2014-02-27 | モーフォテック， インコーポレイテッド | Antifolate receptor alpha antibody glycoforms |
| MX343607B (en) | 2010-11-05 | 2016-11-11 | Morphotek Inc | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers. |
| US9402865B2 (en) | 2011-01-18 | 2016-08-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| KR102101160B1 (en) | 2011-04-01 | 2020-04-16 | 이뮤노젠 아이엔씨 | Methods for increasing efficacy of folr1 cancer therapy |
| AU2012284321C1 (en) | 2011-07-15 | 2017-07-13 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| US9512223B2 (en) | 2012-05-15 | 2016-12-06 | Morphotek, Inc. | Methods for treatment of gastric cancer |
| CA2883222C (en) * | 2012-08-31 | 2021-12-14 | Immunogen, Inc. | Diagnostic assays and kits for detection of folate receptor 1 |
| US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
| CN104884617B (en) | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | Anti- FOLR1 antibody |
| JP6233933B2 (en) | 2012-12-25 | 2017-11-22 | 国立大学法人 鹿児島大学 | Antibodies that recognize folate receptors α and β |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| BR112015028244A2 (en) | 2013-05-14 | 2017-09-19 | Immunogen Inc | IMMUNOCONJUGATE THAT BINDS TO FOLR1 AND ITS USE |
| AU2014284212B2 (en) | 2013-06-20 | 2019-09-12 | Eisai, Inc. | Methods for treatment of ovarian cancer |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| KR102639861B1 (en) | 2013-10-08 | 2024-02-22 | 이뮤노젠 아이엔씨 | Anti-folr1 immunoconjugate dosing regimens |
| EP3077522A1 (en) | 2013-12-04 | 2016-10-12 | Immunogen, Inc. | Compositions and methods for antibody production |
| CA2952876A1 (en) | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof |
| CN107580604A (en) | 2014-09-03 | 2018-01-12 | 伊缪诺金公司 | Conjugate comprising cell binding agent and cytotoxic agent |
| MY184889A (en) * | 2014-11-20 | 2021-04-29 | Hoffmann La Roche | T cell activating bispecific antigen binding molecules |
| EP4141032A1 (en) * | 2014-11-20 | 2023-03-01 | F. Hoffmann-La Roche AG | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CA2983126A1 (en) | 2015-04-17 | 2016-10-20 | Morphotek, Inc. | Methods for treating lung cancer |
| RU2749865C2 (en) | 2015-09-17 | 2021-06-17 | Иммьюноджен, Инк. | Therapeutic combinations containing anti-folr1 immunoconjugates |
| US20190233512A1 (en) | 2016-10-12 | 2019-08-01 | Sutro Biopharma, Inc. | Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| JP2020519675A (en) | 2017-05-16 | 2020-07-02 | イミュノジェン・インコーポレーテッド | Combination of anti-FOLR1 immunoconjugate and anti-PD-1 antibody |
-
2019
- 2019-03-07 BR BR112020016469-0A patent/BR112020016469A2/en unknown
- 2019-03-07 CN CN201980019246.4A patent/CN111954681B/en active Active
- 2019-03-07 JP JP2020548760A patent/JP7433236B2/en active Active
- 2019-03-07 AU AU2019236091A patent/AU2019236091A1/en active Pending
- 2019-03-07 WO PCT/US2019/021084 patent/WO2019177854A1/en unknown
- 2019-03-07 SG SG11202007494TA patent/SG11202007494TA/en unknown
- 2019-03-07 EP EP19767635.6A patent/EP3765521A4/en active Pending
- 2019-03-07 CA CA3091683A patent/CA3091683A1/en active Pending
- 2019-03-07 KR KR1020207028499A patent/KR20200132900A/en not_active Application Discontinuation
- 2019-03-07 CN CN202211567226.0A patent/CN115925952A/en active Pending
- 2019-03-07 EA EA202092125A patent/EA202092125A1/en unknown
- 2019-03-07 US US15/733,541 patent/US11873335B2/en active Active
- 2019-03-07 MX MX2020009522A patent/MX2020009522A/en unknown
-
2020
- 2020-08-26 IL IL276949A patent/IL276949A/en unknown
-
2024
- 2024-02-06 JP JP2024016283A patent/JP2024056787A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3091683A1 (en) | 2019-09-19 |
| CN115925952A (en) | 2023-04-07 |
| EP3765521A4 (en) | 2022-03-23 |
| EA202092125A1 (en) | 2020-12-15 |
| AU2019236091A1 (en) | 2020-09-03 |
| EP3765521A1 (en) | 2021-01-20 |
| JP2021517459A (en) | 2021-07-26 |
| CN111954681A (en) | 2020-11-17 |
| KR20200132900A (en) | 2020-11-25 |
| CN111954681B (en) | 2022-12-06 |
| US20210002363A1 (en) | 2021-01-07 |
| WO2019177854A1 (en) | 2019-09-19 |
| BR112020016469A2 (en) | 2020-12-15 |
| US11873335B2 (en) | 2024-01-16 |
| MX2020009522A (en) | 2020-10-22 |
| IL276949A (en) | 2020-10-29 |
| JP7433236B2 (en) | 2024-02-19 |
| JP2024056787A (en) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276830A (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| SG11202007074PA (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| IL284216B (en) | Anti-transferrin receptor antibodies and uses thereof | |
| IL276950A (en) | Anti-cd73 antibodies and uses thereof | |
| IL273285A (en) | Anti- folate receptor alpha antibody conjugates and their uses | |
| IL278846A (en) | Anti-cd3 antibodies and uses thereof | |
| IL282968A (en) | Anti-nkg2a antibodies and uses thereof | |
| ZA202103061B (en) | Anti-cldn18.2 antibody and uses thereof | |
| IL276949A (en) | Anti-folate receptor 1 antibodies and uses thereof | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL277701A (en) | Anti-chemokin like receptor 1 antibodies and their therapeutic applications | |
| IL275826A (en) | Anti-mct1 antibodies and uses thereof | |
| IL280317A (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| IL290141A (en) | Anti-pvrig antibodies formulations and uses thereof | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL277007A (en) | Therapeutic anti-spla2-gib antibodies and the uses thereof | |
| IL280321A (en) | Anti-cxcr2 antibodies and uses thereof | |
| IL277330A (en) | Anti-il-27 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277075A (en) | Anti-phf-tau antibodies and uses thereof | |
| IL276548A (en) | Bcma-binding antibodies and uses thereof | |
| IL283926A (en) | Anti-alpha-synuclein antibodies and uses thereof | |
| IL281202A (en) | Anti-tnfrsf9 antibodies and uses thereof |